Rutgers & Posch represented NASDAQ listed uniQure N.V. in respect of its $75 million fully underwritten public offering of new ordinary shares.
uniQure is advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases.
Bas Visée and Jamie Pellegrom advised uniQure. Rutgers & Posch teamed up with US firm Morgan Lewis.
For more information read uniQure’s announcements: https://www.uniqure.com/investors-media/press-releases.